How should we treat patients with low serum thyrotropin concentrations?

被引:30
|
作者
Mitchell, Anna L. [2 ]
Pearce, Simon H. S. [1 ,2 ]
机构
[1] Univ Newcastle, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England
[2] Royal Victoria Infirm, Endocrine Unit, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England
基金
英国医学研究理事会;
关键词
SUBCLINICAL THYROID-DYSFUNCTION; FREE-THYROXINE INDEX; STIMULATING HORMONE; OLDER PERSONS; HYPERTHYROIDISM; RISK; TSH; AGE; MANAGEMENT; MORTALITY;
D O I
10.1111/j.1365-2265.2009.03694.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Subclinical hyperthyroidism (SH) is defined by a low serum thyrotropin (TSH) concentration in the presence of normal levels of free thyroxine (FT4) and free triiodothyronine (FT3). However, it is helpful to distinguish between those with a detectable but low TSH value (in the 0 center dot 1-0 center dot 4 mU/l range) and those with a fully suppressed TSH (< 0 center dot 1 mU/l), and we suggest the designation of grade I and grade II SH, respectively. Together, these patterns of thyroid function tests are found in 1-3% of the elderly population, and are associated with significant morbidity and mortality in longitudinal epidemiological surveys. There are a number of causes for this picture, which include endogenous thyroid disease, drug effects and concomitant nonthyroidal illness. Treatments commonly employed in the management of thyrotoxicosis are effective at correcting the biochemical abnormalities of SH but have not been shown to improve clinical outcome or symptoms. There is little good quality evidence available to guide the assessment or management of these patients. This review summarizes the clinical significance of SH and aims to provide guidance about whether we should treat patients with low serum TSH concentrations.
引用
收藏
页码:292 / 296
页数:5
相关论文
共 50 条
  • [1] How should we manage patients with mildly increased serum thyrotrophin concentrations?
    Vanderpump, Mark P. J.
    [J]. CLINICAL ENDOCRINOLOGY, 2010, 72 (04) : 436 - 440
  • [2] How long should we treat porphyric patients?
    Yamamori, I
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 142 (02) : 208 - 208
  • [3] How Should We Treat Patients with Mild Asthma?
    Wong, Gary W. K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (21): : 2064 - 2066
  • [4] OSTEOPOROSIS - HOW SHOULD WE TREAT OUR PATIENTS
    CHRISTIANSEN, C
    [J]. BRITISH JOURNAL OF RHEUMATOLOGY, 1992, 31 : 247 - 247
  • [5] HOW SHOULD WE TREAT OSTEOPOROSIS IN PATIENTS WITH CKD?
    Keen, Richard
    [J]. RHEUMATOLOGY, 2019, 58 : 18 - 18
  • [6] HOW LONG SHOULD WE TREAT OSTEOPOROTIC PATIENTS?
    Brandi, M. L.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S32 - S32
  • [7] How long should we treat?
    Roux, C.
    Briot, K.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 (06) : 1659 - 1666
  • [8] How long should we treat?
    C. Roux
    K. Briot
    [J]. Osteoporosis International, 2014, 25 : 1659 - 1666
  • [9] How should we treat afibrinogenaemia patients with thrombotic complications
    Brand, B.
    Pfammatter, T.
    Amann-Vesti, B.
    Bachli, E.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 538 - 538
  • [10] How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
    Tsimihodimos, Vasilios
    Florentin, Matilda
    Elisaf, Moses S.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (21) : 3773 - 3787